Emergency Medicine Reports (Vol. 37, No. 18) -…

September 15, 2016

View Issues

Drug Interactions

MONOGRAPH: Drug-to-drug interactions represent one of the most significant risks of polypharmacy in our increasingly complex and aging populations.

Read more

Issue Date: September 15, 2016

Financial Disclosure: To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Dr. Farel (CME question reviewer) owns stock in Johnson & Johnson. Dr. Stapczynski (editor) owns stock in Pfizer, Johnson & Johnson, Walgreens Boots Alliance Inc., GlaxoSmithKline, Bristol Myers Squibb, and AxoGen. Dr. Hocum (author) reports he is an employee of United Therapeutics. Dr. Greg Wise (editor) is involved in sales for CNS Vital Signs. Dr. Schneider (editor), Ms. Fessler (nurse planner), Dr. E. Black (author), Kevin Black (author), Dr. Beatty (peer reviewer), Ms. Mark (executive editor), and Ms. Coplin (executive editor) report no financial relationships with companies related to the field of study covered by this CME activity.

Emergency Medicine Reports – September 15, 2016

September 15, 2016

Drug Interactions